Balance Sheet
Cash Flow Statement
Beginning Cash BalanceGains from Sales and Divestitures
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Change in Accured Expenses: 2012-2021

Historic Change in Accured Expenses for RedHill Biopharma (RDHL) over the last 8 years, with Dec 2021 value amounting to -$3.6 million.

  • RedHill Biopharma's Change in Accured Expenses fell 171.85% to -$3.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$1.7 million, marking a year-over-year decrease of 126.44%. This contributed to the annual value of $111,000 for FY2021, which is 98.49% down from last year.
  • Per RedHill Biopharma's latest filing, its Change in Accured Expenses stood at -$3.6 million for Q4 2021, which was down 284.68% from $1.9 million recorded in Q3 2021.
  • RedHill Biopharma's 5-year Change in Accured Expenses high stood at $5.0 million for Q4 2020, and its period low was -$5.0 million during Q2 2021.
  • Its 3-year average for Change in Accured Expenses is -$46,286, with a median of $1.1 million in 2019.
  • In the last 5 years, RedHill Biopharma's Change in Accured Expenses soared by 532.35% in 2017 and then plummeted by 402.20% in 2021.
  • RedHill Biopharma's Change in Accured Expenses (Quarterly) stood at -$3.1 million in 2017, then reached $1.1 million in 2019, then crashed by 191.74% to $5.0 million in 2020, then crashed by 171.85% to -$3.6 million in 2021.
  • Its Change in Accured Expenses stands at -$3.6 million for Q4 2021, versus $1.9 million for Q3 2021 and -$5.0 million for Q2 2021.